Ethnic distribution of factor V Leiden in 4047 men and women: Implications for venous thromboembolism screening

JAMA

Volumn 277, Issue 16, 1997, Pages 1305-1307

  Ridker, Paul M ^a,c   Miletich, Joseph P ^b   Hennekens, Charles H ^a   Buring, Julie E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5;

ADULT; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; ETHNIC DIFFERENCE; FEMALE; GENE MUTATION; HUMAN; MALE; NORMAL HUMAN; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCREENING; THROMBOEMBOLISM;

EID: 0030955080     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.277.16.1305     Document Type: Article

References (33)

1. Goldhaber SZ. Pulmonary Embolim and Deep Venous Thrombosis Philadlphia, Pa: WB Saunders Co; 1985.
2. Anderson FA, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. Arch Intern Med. 1991;151:933-938.
3. Kniffin WD, Baron JA, Barret J, et al. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Mad. 1994;154:861-866.
4. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-67.
5. Zoller B, Dahlback B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet. 1994;343:1536-1538.
6. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoaglant response to activated protein C. Proc Natl Acad Sci U S A. 1993;90:1004-1008.
7. Koster T, Rosendaal FR, de Ronde H, et al. Venous thrombosis due to poor anticoagulant response to activated protein C. Lancet. 1993;342:1503-1506.
8. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994;330:517-522.
9. Ridker PM, Hennekens CH, Lindpaintner K, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995;332:912-917.
10. Ridker PM, Miletich JP, Stampfer MJ, et al. Factor V Leiden and risks fo recurrent idiopathic venous thromboembolim. Circulation. 1995;92:2800-2802.
11. 506→Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med. 1997;336:399-403.
12. Dahlback B. Are we ready for factor V Leiden screening? Lancet. 1996;347:1346-1347.
13. Vandenbrouke JP, Koster T, Briet E, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344:1453-1457.
14. Bloemenkamp KWM, Rosendaal FR, Helmer horst FM, et al. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing third-generation progestagen. Lancet. 1995;346:1593-1596.
15. Hellgren M, Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol. 1995;173:210-213.
16. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden, Lancet. 1995;348:1133-1134.
17. Steering Committee of the Physicians' Health Study Research Group. Final report of the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129-135.
18. Buring JE, Hennekens CH, for the Women's Health Study Research Group. The Women's Health Study. J Myocard Ischem. 1992;4:27-29.
19. Rosen S, Johansson K, Lindberg K, et al, for the APC Resistance Study Group. Multicenterevaluation of a kit for activated protein C resistance on various coagulation instruments using plasma from healthy individuals. Thromb Haemost. 1994;72:255-260.
20. Ridker PM, Glynn RJ, Miletich JP, et al. Agespecific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden. Ann Intern Med. 1997;126:528-531.
21. Ridker PM, Hennekens CH, Selhub J, et al. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risks of future venous thromboembolism. Circulation. 1997;95:1777-1782.
22. Koeleman BPC, Reitsma PH, Allaart CF, et al. Activated protein C resistance as an additional risk factor for thrombosis in protein C deficient families. Blood. 1994;84:1031-1035.
23. Koeleman BPC, van Rumpt D, Hamulyak K, et al. Factor V Leiden. Thromb Haemost. 1995;74:580-583.
24. Chan LC, Bourke C, Lam CK, et al. Lack of activated protein C resistance in healthy Hong Kong Chinese blood donors. Thromb Haemost. 1996;75:522-523.
25. Takamiya O, Ishida F, Kodaira H, Kitano K. APC-resistance and Mnl I genotype (Gln 506) of coagulatoin factor V are rare in Japanese population. Thromb Haemost. 1995;74:996.
26. Burkitt DP. Varicose veins, deep venous thrombosis, and haemorrhoids. BMJ. 1972;2:556-561.
27. Nathwani AC, Tuddenharn EGD. Epidemiology of coagulation disorders. Baillieres Clin Haematol. 1992;5:383-439.
28. Duthie SJ, Ghosh A, Ma HK. Maternal mortality in Hong Kong, 1961-1985. Br J Obstet Gynaecol. 1989; 96:4-8.
29. Tso SC, Wong V, Chan V, et al. Deep vein thrombosis and changes in coagulation and fibrinolysis after gynaecological operations in Chinese. Br J Haematol. 1980;46:603-612.
30. Kost K, Forrest JD, Harlap S. Comparing the health risks and benefits of contraceptive choices. Fam Plann Perspect. 1991;23:54-61.
31. United States Population Estimates, by Age, Sex, Race, and Hispanic Origin, 1990 to 1995. Washington, DC: US Bureau of the Census, Population Division. Release PPL-41. Availalilc at hltp://www. census.gov. Accessed August 16, 1996.
32. Peterson LS. Comtraceptive Use in the United States, 1982-1990: Advance Data From Vital and Health Statistics. Hyattsville, Md: National Center for Health Statistics; 1995; 260:1-15.
33. Vandenbroucke JP, van der Meer FJM, Helmerhorst FM, Rosendaal FR. Factor V Leiden. BMJ. 1996;313:127-1130.